Summary
7.99 -0.15(-1.78%)09/06/2024
Biocryst Pharmaceuticals Inc. (BCRX)
Biocryst Pharmaceuticals Inc. (BCRX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.72 | -8.11 | 1.33 | 23.89 | 53.26 | 14.07 | 154.30 | 22.85 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 7.99 | |
| Open | 8.15 | |
| High | 8.25 | |
| Low | 7.91 | |
| Volume | 1,034,879 | |
| Change | -0.14 | |
| Change % | -1.72 | |
| Avg Volume (20 Days) | 1,435,371 | |
| Volume/Avg Volume (20 Days) Ratio | 0.72 | |
| 52 Week Range | 4.03 - 8.88 | |
| Price vs 52 Week High | -10.08% | |
| Price vs 52 Week Low | 98.14% | |
| Range | -2.02 | |
| Gap Up/Down | -0.16 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,651 | |
| EBIDTA | -82,086,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.2800 | |
| WallStreet Target Price | 14.00 | |
| Book Value | -2.3080 | |
| Earnings Per Share | -1.0700 | |
| EPS Estimate Current Quarter | -0.2100 | |
| EPS Estimate Next Quarter | -0.1600 | |
| EPS Estimate Current Year | -0.6200 | |
| EPS Estimate Next Year | -0.3700 | |
| Diluted EPS (TTM) | -1.0700 | |
| Revenues | ||
| Profit Marging | -0.5869 | |
| Operating Marging (TTM) | -0.1562 | |
| Return on asset (TTM) | -0.1085 | |
| Return on equity (TTM) | -19.2537 | |
| Revenue TTM | 355,395,008 | |
| Revenue per share TTM | 1.8080 | |
| Quarterly Revenue Growth (YOY) | 0.3490 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 10,936,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 56.5858 | |
| Revenue Enterprise Value | 4.2832 | |
| EBITDA Enterprise Value | -12.2018 | |
| Shares | ||
| Shares Outstanding | 206,376,992 | |
| Shares Float | 191,427,132 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.16 | |
| Insider (%) | 1.04 | |
| Institutions (%) | 88.54 | |
09/06 02:00 EST - globenewswire.com
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of six posters, including the first interim real-word evidence from the APeX-N trial, and new data highlighting the value of shared decision making (SDM) between healthcare providers (HCPs) and their hereditary angioedema (HAE) patients to provide optimal patient outcomes.
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of six posters, including the first interim real-word evidence from the APeX-N trial, and new data highlighting the value of shared decision making (SDM) between healthcare providers (HCPs) and their hereditary angioedema (HAE) patients to provide optimal patient outcomes.
09/04 07:00 EST - globenewswire.com
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired employees stock options to purchase an aggregate of 28,400 shares, and restricted stock units (RSUs) covering an aggregate of 20,025 shares, of BioCryst common stock. The options and RSUs were granted as of August 30, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired employees stock options to purchase an aggregate of 28,400 shares, and restricted stock units (RSUs) covering an aggregate of 20,025 shares, of BioCryst common stock. The options and RSUs were granted as of August 30, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
08/22 07:00 EST - globenewswire.com
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
08/05 11:44 EST - seekingalpha.com
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2024 Earnings Call Transcript August 5, 2024 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Anthony Doyle - CFO Helen Thackray - Chief R&D Officer Conference Call Participants Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Chris Raymond - Piper Sandler Gena Wang - Barclays Maury Raycroft - Jefferies Stacy Ku - TD Cowen Jon Wolleben - JMP Securities Serge Belanger - Needham & Company Operator Good day and welcome to the BioCryst Second Quarter 2024 Earnings Call. All participants will be in listen-only mode.
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2024 Earnings Call Transcript August 5, 2024 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Anthony Doyle - CFO Helen Thackray - Chief R&D Officer Conference Call Participants Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Chris Raymond - Piper Sandler Gena Wang - Barclays Maury Raycroft - Jefferies Stacy Ku - TD Cowen Jon Wolleben - JMP Securities Serge Belanger - Needham & Company Operator Good day and welcome to the BioCryst Second Quarter 2024 Earnings Call. All participants will be in listen-only mode.
08/05 11:01 EST - zacks.com
Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for BioCryst (BCRX) points to a 99.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for BioCryst (BCRX) points to a 99.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
08/05 09:11 EST - zacks.com
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.
08/05 07:00 EST - globenewswire.com
BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
—Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates GAAP operating profit of $8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipeline continues to advance— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.
BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
—Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates GAAP operating profit of $8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipeline continues to advance— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.
07/30 12:25 EST - investorplace.com
7 Small-Cap Stocks to Buy for Large-Scale Gains
Small-capitalization companies represent high-risk endeavors. At the same time, they generally carry higher reward potential.
7 Small-Cap Stocks to Buy for Large-Scale Gains
Small-capitalization companies represent high-risk endeavors. At the same time, they generally carry higher reward potential.
07/29 11:06 EST - zacks.com
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/22 07:00 EST - globenewswire.com
BioCryst to Report Second Quarter 2024 Financial Results on August 5
RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024.
BioCryst to Report Second Quarter 2024 Financial Results on August 5
RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024.
07/21 07:30 EST - seekingalpha.com
Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects
BioCryst Pharmaceuticals develops complement-mediated and rare disease treatments using a structure-guided drug design process. The company's pipeline also includes promising drug candidates in pivotal phases and pre-clinical stages. The company relies heavily on Orladeyo, which represents 95.8% of its total revenues.
Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects
BioCryst Pharmaceuticals develops complement-mediated and rare disease treatments using a structure-guided drug design process. The company's pipeline also includes promising drug candidates in pivotal phases and pre-clinical stages. The company relies heavily on Orladeyo, which represents 95.8% of its total revenues.
07/18 13:02 EST - zacks.com
BioCryst (BCRX) Upgraded to Strong Buy: Here's Why
BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
BioCryst (BCRX) Upgraded to Strong Buy: Here's Why
BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
07/18 10:56 EST - zacks.com
Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 92.6% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 92.6% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
07/09 07:00 EST - globenewswire.com
ORLADEYO® (berotralstat) Approved in Peru
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.
ORLADEYO® (berotralstat) Approved in Peru
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.
06/02 04:00 EST - globenewswire.com
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis options Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis options
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis options Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis options
05/14 07:00 EST - globenewswire.com
BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Valencia, Spain from May 31 to June 3, 2024.
BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Valencia, Spain from May 31 to June 3, 2024.
05/13 07:00 EST - globenewswire.com
ORLADEYO® (berotralstat) Approved in Mexico
RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.
ORLADEYO® (berotralstat) Approved in Mexico
RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.